📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Heranba Industries to Convert ₹450 Cr ICDs into OFCDs of Subsidiary Heranba Organics
Heranba Industries has approved the conversion of ₹450 crore in existing unsecured Inter-Corporate Deposits (ICDs) provided to its wholly-owned subsidiary, Heranba Organics Private Limited (HOPL), into Optionally Fully Convertible Debentures (OFCDs). This internal restructuring involves the issuance of 45 crore OFCDs at a face value of ₹10 each on a private placement basis. The transaction does not involve any fresh cash outflow and is designed to restructure the debt profile of the subsidiary. HOPL, which operates in the agrochemicals sector, showed significant growth with a turnover of ₹220.58 crore in FY 2024-25 compared to just ₹0.27 crore in the previous year.
Key Highlights
Conversion of ₹450 crore unsecured ICDs into 45,00,00,000 OFCDs at a face value of ₹10 each
Target entity Heranba Organics Private Limited (HOPL) is a 100% material unlisted subsidiary
HOPL reported a substantial turnover increase to ₹220.58 crore in FY 2024-25 from ₹0.27 crore in FY 2023-24
The restructuring involves no fresh cash outflow and maintains 100% parent control
The transaction was conducted on an arm's-length basis as part of internal debt management
💼 Action for Investors
As this is an internal financial restructuring with no cash outflow, it has no immediate impact on consolidated valuations. Investors should focus on the rapid scaling of the subsidiary HOPL as a potential future growth driver for the parent company.
Loading analysis...
Heranba Industries to Convert ₹450 Cr Subsidiary Loan into 10-Year Convertible Debentures
Heranba Industries has approved the conversion of ₹450 crore in Inter-Corporate Deposits (ICDs) provided to its wholly-owned subsidiary, Heranba Organics Private Limited, into Optionally Fully Convertible Debentures (OFCDs). This restructuring formalizes the internal funding into a long-term instrument with a 10-year tenure and a nominal 1% annual interest rate. The OFCDs provide the parent company the option to convert the debt into equity shares of the subsidiary in the future. Since this is an internal transaction between a parent and its 100% subsidiary, it has no immediate impact on consolidated financial performance.
Key Highlights
Conversion of ₹450 crore existing Inter-Corporate Deposits into Optionally Fully Convertible Debentures (OFCDs).
The new debentures carry a long-term tenure of 10 years.
The coupon rate is set at a nominal 1% per annum, significantly lower than market debt rates.
The transaction is aimed at restructuring existing inter-company funding on an arm's length basis.
💼 Action for Investors
No immediate action is required as this is a balance sheet reclassification of existing internal funds. Investors should monitor the operational progress of the subsidiary, Heranba Organics, to evaluate the long-term value of the conversion option.
Loading analysis...
Heranba Launches New Crop Nutrition Products; Targets ₹2,500 Cr Revenue in FY26
Heranba Industries has strategically entered the high-growth crop nutrition segment with the launch of two new products, Fentaamine and MycoHil, developed in collaboration with an American MNC. The company has set an ambitious total revenue target of ₹2,500 crore for the current fiscal year, supported by its entry into this segment which is growing at a 15% CAGR. Expansion plans also include establishing a subsidiary in Dubai to penetrate Middle Eastern and African markets. This diversification leverages Heranba's seven manufacturing facilities and aims to move beyond its core synthetic pyrethroids business.
Key Highlights
Launched Fentaamine (bio-stimulant) and MycoHil (bio-fertilizer) in collaboration with a leading American MNC
Set an ambitious total revenue target of ₹2,500 crore for the current fiscal year
Targeting the crop nutrition segment which is growing at a CAGR of over 15% globally and in India
Plans to establish a subsidiary in Dubai to strengthen presence across 80+ countries
Leveraging 7 world-class manufacturing facilities to scale up CMO operations and brand equity
💼 Action for Investors
Investors should monitor the company's ability to meet the ₹2,500 crore revenue guidance and the market's response to the new bio-stimulant products. The diversification into high-growth segments and global expansion via a Dubai subsidiary are strong positive indicators for long-term value.
Loading analysis...
Heranba Industries Faces ₹2.63 Crore Insolvency Petition Over Quality Dispute
Haresh Petrochem Private Limited has filed an insolvency application against Heranba Industries Limited under the IBC for a claim of approximately ₹2.63 Crores. Heranba has clarified that the payment was withheld due to quality issues with the goods supplied and is actively working to resolve the matter. The company expects to settle the dispute amicably outside of the NCLT proceedings. While the filing is a material event, the relatively small claim amount suggests it is a commercial dispute rather than a sign of systemic financial distress.
Key Highlights
Insolvency petition filed under Section 9 of the IBC at NCLT Ahmedabad.
Claim amount involved is approximately ₹2.63 Crores.
Non-payment attributed to quality issues in goods/services provided by the petitioner.
Next hearing date for the matter is scheduled for April 20, 2026.
Management expects an out-of-court settlement with no long-term impact on operations.
💼 Action for Investors
Investors should monitor the situation until the next hearing on April 20, 2026, to ensure a settlement is reached. Given the small claim size relative to Heranba's scale, this is likely a tactical legal move by a creditor rather than a solvency crisis.
Loading analysis...
IBC Insolvency Application Filed Against Heranba Subsidiary Over Rs 93.90 Lakh Claim
Haresh Petrochem Private Limited has filed an insolvency petition under the IBC against Heranba Organics Private Limited, a 100% subsidiary of Heranba Industries. The initial claim was approximately Rs 1.70 Crores, which has been reduced to an outstanding balance of Rs 93.90 Lakhs following part payments. The company states the remaining balance is withheld due to quality disputes regarding the supplied goods. Management expects to settle the matter amicably outside the NCLT framework once the quality issues are addressed.
Key Highlights
Insolvency application filed under Section 9 of IBC against 100% subsidiary Heranba Organics.
Total claim amount reduced from Rs 1.70 Crores to an outstanding balance of Rs 93.90 Lakhs.
Payment withheld by the subsidiary due to unresolved quality issues with the petitioner's supplies.
Management expects an out-of-court settlement and does not anticipate long-term material impact.
💼 Action for Investors
Monitor the progress of the NCLT proceedings to ensure the settlement is reached as planned. While the claim amount is small, any escalation in insolvency proceedings for a subsidiary requires caution.
Loading analysis...
Heranba Q3: Consolidated Net Loss Widens to ₹23.29 Cr; Standalone Profit at ₹9.32 Cr
Heranba Industries reported a weak set of consolidated numbers for Q3 FY26, with the net loss widening to ₹23.29 crore from a loss of ₹10.37 crore in the same quarter last year. Consolidated revenue from operations declined to ₹305.17 crore, down from ₹341.29 crore year-on-year. While standalone operations turned profitable at ₹9.32 crore compared to a loss last year, the consolidated performance was dragged down by higher finance costs and depreciation. The company also announced the appointment of ZMAS and Associates as the new Internal Auditor.
Key Highlights
Consolidated revenue from operations fell to ₹305.17 crore in Q3 FY26 from ₹341.29 crore in Q3 FY25.
Consolidated net loss widened significantly to ₹23.29 crore versus a loss of ₹10.37 crore YoY.
Standalone profit stood at ₹9.32 crore, a recovery from a standalone loss of ₹9.12 crore in the previous year's quarter.
Consolidated finance costs doubled to ₹12.39 crore from ₹6.15 crore in the year-ago period.
Consolidated depreciation and amortisation expenses rose sharply to ₹25.67 crore from ₹14.03 crore YoY.
💼 Action for Investors
Investors should exercise caution as widening consolidated losses and rising finance costs indicate significant pressure on the bottom line. The divergence between standalone profit and consolidated loss suggests underperformance in subsidiary operations that requires further scrutiny.
Loading analysis...
Heranba Q3 Results: Standalone Profit of ₹9.32 Cr; Consolidated Net Loss Widens to ₹23.29 Cr
Heranba Industries reported a mixed Q3 FY26, with standalone operations turning profitable at ₹9.32 crore despite a 9.4% YoY revenue dip to ₹306.55 crore. However, the consolidated picture is concerning as net losses widened to ₹23.29 crore from ₹10.37 crore YoY. This deterioration is largely driven by a sharp spike in consolidated depreciation (₹25.67 crore vs ₹14.03 crore) and finance costs (₹12.39 crore vs ₹6.15 crore). The company also announced the appointment of ZMAS and Associates as internal auditors.
Key Highlights
Standalone Net Profit of ₹9.32 crore vs a loss of ₹9.12 crore in Q3 FY25.
Consolidated Net Loss widened significantly to ₹23.29 crore from ₹10.37 crore YoY.
Consolidated Finance Costs surged 101% YoY to ₹12.39 crore.
Consolidated Depreciation and Amortization increased by 83% YoY to ₹25.67 crore.
Nine-month consolidated revenue showed growth at ₹1,235.58 crore vs ₹1,074.96 crore YoY.
💼 Action for Investors
The widening consolidated loss despite standalone profitability suggests significant drag from subsidiaries or new capital expenditures not yet yielding returns. Investors should wait for management commentary on margin recovery and debt levels before taking new positions.
Loading analysis...
Heranba Subsidiary to Incorporate UAE Unit with INR 2 Crore Initial Investment
Heranba Industries Limited has announced that its wholly-owned subsidiary, Mikusu India Private Limited, will establish a new 100% subsidiary in the United Arab Emirates. The new entity will focus on the agro-chemical business, specifically pesticides, insecticides, and herbicides. An initial cash investment of up to INR 2.00 crores is planned for this expansion. This strategic move aims to enhance the company's global footprint and distribution capabilities in the Middle East.
Key Highlights
Board of Mikusu India Private Limited approved the 100% WOS in UAE on January 14, 2026.
Proposed initial investment in the UAE subsidiary is up to INR 2.00 crores in cash.
The entity will deal in chemical products including fungicides, weedicides, and pesticides.
RBI approval will be required for the remittance of Outward Direct Investment (ODI) post-inception.
💼 Action for Investors
Investors should view this as a positive step toward international market penetration. Monitor the progress of the UAE subsidiary's incorporation and its eventual contribution to the company's export revenue.